Could cause temporary or reversible harm; serious harm is unlikely.
CGMP Deviations: Discontinuation of the Quality program by manufacturer that would assure product meet the identity, strength, quality, and purity characteristics that they are purported or represented to possess.
| Distributed by / for | Meda pharmaceuticals Inc. (a Viatris company) Somerset New Jersey 00873-4120 |
| NDC | 0037-9001-05 |
| Full product label | Levsin injection (hyoscyamine sulfate injection, USP), 0.5 mg per ml in water for Injection, 1 ml Ampule (Box of 5 ampules), Rx Only, Distributed by: Meda pharmaceuticals Inc. (a Viatris company) Somerset New Jersey 00873-4120, NDC #0037-9001-05 |
| Recalling firm | Viatris Inc |
| Distribution | Product was distributed to 10 distributors who may have further distribute the product to the retail level. |
| Quantity | 2,736 boxes |
| Recall initiated | 2023-05-25 |
| Report date | 2023-06-14 |
| Recall completed | 2024-04-11 |
| Recall number | D-0866-2023 |
| Classification | Class II |
| FDA status | Terminated |
| Origin on file | Canonsburg PA United States |
Source: U.S. FDA enforcement database (openFDA). Look this up on the official FDA recalls site ↗